STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more

Exclusive Megan Molteni

STAT Plus: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership

Exclusive Mohana Ravindranath

STAT Plus: Startup Q Bio raises $27 million to build its own full-body scanner

Politics Rachel Cohrs Zhang and John Wilkerson

STAT Plus: Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump

Pharma Andrew Joseph

STAT Plus: Novartis hedges on when it might submit myelofibrosis drug for approval

Business Tara Bannow

STAT Plus: Elevance tumbles as health insurer warns Medicaid members are using more care

Adam's Take Adam Feuerstein

STAT Plus: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world

Biotech Elaine Chen

STAT Plus: Gilead’s chief medical officer to leave as R&D efforts stall

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more

Health tech Mohana Ravindranath

STAT Plus: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden

Pharmalot Ed Silverman and Rachel Cohrs Zhang

STAT Plus: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down

Health tech Mario Aguilar

STAT Plus: Why clinical trials for digital therapeutics are getting more rigorous

Biotech Allison DeAngelis

STAT Plus: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund

Exclusive Nicholas Florko

STAT Plus: Applesauce lead contamination could not have been prevented, top FDA official suggests

Business Tara Bannow

STAT Plus: UnitedHealth CEO concedes company was ‘over-optimistic’ about Change cyberattack recovery

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more

Exclusive Mohana Ravindranath

STAT Plus: A cancer care startup is making a new bet with payers and providers: only pay if it works

Health Care Inc. Bob Herman

STAT Plus: Medicare pay proposals are good news for health tech, bad news for docs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more

Biotech Jason Mast

STAT Plus: Early data from Lexeo’s gene therapy for rare heart disease shows promise

Politics John Wilkerson

STAT Plus: The effort to reform physician pay is set to pit primary care docs against highly paid specialists

Exclusive Nicholas Florko

STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more

In the Lab Rohan Rajeev

STAT Plus: The biggest misconception about CTE, according to a leading brain trauma expert

Health tech Mario Aguilar

STAT Plus: Medicare proposes to cover some digital therapies in a breakthrough for health tech firms

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more

Pharma Matthew Herper and Elaine Chen

STAT Plus: Pfizer says it will advance once-daily GLP-1 pill after all

Adam's Take Adam Feuerstein

STAT Plus: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?